Entrada Q3 net loss narrows to $39.7 million; collaboration revenue falls
Entrada Therapeutics reported third-quarter 2026 results with a net loss of $39.7 million, down from $44.1 million a year earlier, as research and development expenses fell to $32.4 million from $38.4 million. Collaboration revenue dropped to $0.9 million from $1.6 million, and cash, cash equivalents and marketable securities fell to $193.0 million from $295.7 million at December 31, 2025, which the company says extends its cash runway into the fourth quarter of 2027.
Key points
- Q3 2026 net loss was $39.7 million, compared with $44.1 million in Q3 2025.
- Collaboration revenue was $0.9 million, compared with $1.6 million in Q3 2025.
- R&D expenses were $32.4 million, compared with $38.4 million; G&A expenses were $10.2 million, compared with $10.3 million.
- Cash, cash equivalents and marketable securities were $193.0 million as of September 30, 2026, versus $295.7 million at December 31, 2025, with runway stated into Q4 2027.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.